ReNeuron Group PLC (LON:RENE) said it expects data from the three-month extension segment of a Phase 2a study of its stem cell treatment for retinal disease retinitis pigmentosais in the fourth quarter this year.
This will add to data gleaned already including efficacy signals in some patients receiving treatment for 12 months, added the biotech.
ReNeuron added the enrolment of patients in the trial had now restarted again following a temporary halt in May.
Elsewhere, the AIM-listed firm said it also expects proof-of-concept data from its exosome research collaborations in the fourth quarter of this year (2021).
Olav Hellebo, chief executive, added: “Over the previous financial year, we have been successful in designing and implementing an extension cohort in the phase 2a clinical trial of our hRPC cell therapy candidate in retinitis pigmentosa, including doubling of the dose and other changes designed to amplify the efficacy signal seen in earlier cohorts.
“We have received regulatory approvals in the US, UK and Spain, and have started enrolment in all countries.
“Although dosing was temporarily suspended during the investigation of a presumed bacterial infection, the clinical trial is being restarted, and we expect subjects to be treated shortly, with further data to be presented later in Q4 2021.
“Our exosome and iPSC platforms have also progressed well during the period, with multiple industry-based collaborations now in progress across both platforms and the prospect of pre-clinical proof-of-concept data over the coming months.
“Our decision in 2020 to focus the Company’s resources on our retinal disease programme and our exosome and iPSC platforms has resulted in significantly lower operating costs, as reflected in the results for the year. “
Revenues in the year to March, 2021, were GBP257,000 (GBP6mln) with a loss for the year of GBP11.3mln (GBP11.4mln).
Cash and equivalents were GBP22/2mln at the end of the period giving a runway of at least 12months from now, ReNeuron added.